Expiry of extended deadline for submitting lists for the appointment of the Board of Statutory Auditors: no lists were presented by minority Shareholders
With reference to the Shareholders’ Meeting of MolMed S.p.A. (MLM.MI), convened for 22 April 2013 on single call to decide, among other items, on the appointment of members of the Board of Statutory Auditors, MolMed announces that no lists for such appointment was filed by minority Shareholders – with minimum threshold necessary for the submission reduced by half – on expiry of the extended deadline, i.e. today at 6:00 PM. Please note that, as reported in the press release of 29 March 2013, the lists (and related documentation) submitted by Shareholders Fininvest S.p.A., Science Park Raf S.p.A. winding-up, Airain Lda, Delfin S. à r.l. and H-Equity S.r.l. – members of the shareholders’ agreement entered into on 14 December 2007 as subsequently amended – who certified the ownership of 35.319% of the ordinary shares of the Company, are available (in Italian) on MolMed’s website (http://www.molmed.com/node/2161).
This press release is written in compliance with public disclosure obligations established by CONSOB (Italian securities & exchange commission) resolution no. 11971 of 14 May 1999, as subsequently amended.
About MolMed
MolMed S.p.A. is a biotechnology company focused on research, development and clinical validation of novel anticancer therapies. MolMed’s pipeline includes two antitumour therapeutics in clinical development: TK, a cell-based therapy enabling bone marrow transplants from partially compatible donors, in absence of post-transplant immune-suppression, in Phase III in high-risk acute leukaemia;NGR-hTNF, a novel vascular targeting agent, in Phase III in malignant pleural mesothelioma and in Phase II in six more indications: colorectal, lung (small-cell and non-small-cell), liver and ovarian cancer, and soft tissue sarcomas. MolMed also offers top-level expertise in cell and gene therapy to third parties to develop, conduct and validate projects from preclinical to Phase III trials, including scale-up and cGMP production of clinical-grade viral vectors, and manufacturing of patient-specific genetically engineered cells. MolMed is headquartered at the San Raffaele Biomedical Science Park in Milan, Italy. The Company’s shares are listed on the main market (MTA) of the Milan Stock Exchange. (Ticker Reuters: MLMD.MI)
Source: MolMed